Jiangsu Hengxing Technology Registers for IPO on Shanghai Stock Exchange, Plans to Raise 900 Million Yuan
Jiangsu Hengxing New Material Technology Co., Ltd. (Hengxing Technology) recently registered for an initial public offering (IPO) on the Shanghai Stock Exchange (SSE) main board, with plans to raise 900 million yuan. The company had previously filed for an IPO on the ChiNext board in 2021 but withdrew its application after being selected for an on-site inspection, which lasted only 40 days.
Hengxing Technology is a fine chemical company that procures bulk chemicals as raw materials and focuses on the organic ketone, organic ester, and organic acid industry chains, effectively utilizing and developing high-value-added, downstream market-oriented fine chemical products.
According to the prospectus, Hengxing Technology's revenue was 428 million yuan, 518 million yuan, and 677 million yuan in 2020, 2021, and 2022, respectively. Its net profit was 125 million yuan, 89.72 million yuan, and 93.28 million yuan, respectively, while its net profit after deducting non-recurring items was 122 million yuan, 87.71 million yuan, and 92.826 million yuan, respectively.
2026-09-07
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Urea Prices Surge as India Faces Critical Shortages: Will China’s Export Quotas Provide Relief?
-
COIM Group Expands Alkyd and Acrylic Resin Production Capacity in the Netherlands
-
German Chemical Industry Posts Q2 Rebound but Capacity Utilization Remains at 73.2%
-
U.S. 10% Temporary Tariff Expires, New Section 301 Tariffs Not Yet Implemented
-
Chinese Urea Producers Receive a Timely Boost as Second Round of 2026 Export Quotas Nears 2 Million Tons
-
New York Targets Additives and GRAS Disclosure
-
India Raises Cancer Drug Price Caps by 50%
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Biologicals Move from Trial Plots to Real Distribution
Recommend Reading
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Polyvantis Opens Shanghai Technical Center
-
Spain’s Data-Protection Confusion Hits Pesticide Competitiveness
-
The domestic butadiene rubber market shows a slight weakening
-
Strong Supply and Weak Demand Continues, PP Fluctuates and Falls in November
-
In November, the market price of anhydrous hydrogen fluoride in China showed a downward trend
-
November epoxy chloropropane market first fell then stabilized
-
Costs Decline, Production Starts to Rise—Phthalic Anhydride Prices Fluctuate and Fall in November